Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsMatthew J. Sale, Simon J. Cook|Nature Communications|2019Cited by 73
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistanceMatthew J. Sale, Simon J. Cook|Nature Communications|2019Cited by 60